To compare the presentation and short-term results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis (LPSP) and pancreatic adenocarcinoma (PA) and to provide long-term follow-up on patients undergoing resection for LPSP.
Objective
To compare the presentation and short-term results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis (LPSP) and pancreatic adenocarcinoma (PA) and to provide long-term follow-up on patients undergoing resection for LPSP.
Summary Background Data
LPSP is a rare form of chronic pancreatitis characterized by a mixed inflammatory infiltrate centered around pancreatic ducts and ductules, combined with obliterative phlebitis. Its presentation may mimic that of PA. Among 1, 648 patients undergoing pancreaticoduodenectomy at the authors' institution from January 1992 to May 2002, 37 with LPSP were identified. The demographics, clinical features, and short-and long-term outcomes of these patients were analyzed. Where applicable, comparisons were made to a consecutive group of 45 patients who underwent pancreaticoduodenectomy for PA from July 2001 to December 2001.
Methods

Results
Twenty-four percent (9/37) of the LPSP patients and none of the PA patients had a history of either atopic or autoimmune disease. The LPSP patients had a similar clinical presentation to the PA patients, but the LPSP patients were less likely to have a discrete pancreatic mass on CT and more likely to have CT findings suggesting a diffusely enlarged pancreas. The LPSP patients were also less likely to have a discrete pancreatic mass at operation, more likely to have a diffusely firm or hard gland, and more likely to have a difficult portal vein/superior mesenteric vein dissection when compared to the PA patients. Transfusion requirement, operative time, postoperative length of stay, and overall complication rate were similar between groups; however, the LPSP patients had a greater operative blood loss. The median length of follow-up for LPSP patients was 33 months. No patients had recurrent jaundice. One patient with LPSP had clinically evident recurrent pancreatitis. Among LPSP patients available for current telephone interview, 68% subjectively rated their quality of life as better, 18% reported no change, and 14% reported diminished quality of life compared to before surgery.
Conclusion
LPSP mimics PA in clinical presentation, though CT findings of a diffusely enlarged pancreas without a discrete mass may suggest a diagnosis of LPSP. Nevertheless, differentiation from pancreatic neoplasia remains difficult. Patients undergoing pancreaticoduodenectomy for LPSP have durable relief of symptoms and a subjectively improved quality of life.
In 1961, Sarles et al. first described a condition called "primary inflammatory sclerosis of the pancreas." 1 Today, this condition is more commonly known as autoimmune pancreatitis or lymphoplasmacytic sclerosing pancreatitis (LPSP). 2,3 LPSP is characterized histologically by a diffuse lymphoplasmacytic infiltrate centered around pancreatic ducts and ductules, accompanied by obliterative phlebitis, acinar atrophy, and interstitial fibrosis. 1, [3] [4] [5] [6] [7] It occurs in the absence of gallstone pancreatitis, pancreas divisum, or excess alcohol ingestion. LPSP occurs alone or in association with Sjogren syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, Crohn disease, or ulcerative colitis. 6,8 -11 LPSP, which has been most extensively studied by Japanese investigators, generally presents with a combination of abdominal pain, weight loss, and jaundice. 2, 3, [12] [13] [14] [15] [16] [17] [18] Given this, the presentation of LPSP may mimic that of pancreatic cancer. When recognized preoperatively, LPSP has been treated with systemic steroids, often with resolution of symptoms. 2, 12, 13, 15, [17] [18] [19] Based on increased clinical awareness of this entity and ongoing uncertainty regarding optimal management, we sought to review preoperative, intraoperative, and short-and long-term outcomes for patients undergoing pancreaticoduodenectomy for LPSP at our institution.
METHODS
From January 1992 to May 2002, 1,648 pancreaticoduodenectomies were performed at our institution, of which 1,398 were for neoplasia (including 689 for pancreatic ductal adenocarcinoma), 176 were for chronic pancreatitis, and 74 were for other indications. The 176 cases of chronic pancreatitis were reviewed and 37 were pathologically classified as LPSP. This classification was based on the histologic findings of a prominent mixed inflammatory infiltrate centered around pancreatic ducts, periductal fibrosis, duct destruction, and obliterative phlebitis ( Fig. 1 ). 20, 21 Using both a prospective database and a retrospective chart review, the demographics, clinical features, and short-term outcomes of these patients were analyzed. Where applicable, comparisons were made to a consecutive group of 45 patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma (PA) from July 2001 to December 2001. Finally, via telephone interview, the LPSP patients were questioned regarding persistent symptoms, intervening operations, and quality of life. Data were analyzed using SPSS software (SPSS Inc., Chicago, IL). Significance was defined as P Յ .05.
RESULTS
The mean age of the 37 LPSP patients was 62 years and that of the 45 PA patients was 67 years. Twenty-four percent (9/37) of the LPSP patients were female as opposed to 64% (29/45) of the PA patients (P Ͻ .05). Twenty-four percent (9/37) of the LPSP patients had a history of either atopic or autoimmune disease (asthma, n ϭ 6; Sjogren syndrome, n ϭ 1; ulcerative colitis, n ϭ 2) as compared to none of the PA patients (P Ͻ .05). There were no differences in the incidence of diabetes mellitus, acute pancreatitis, or self-reported alcohol use between the two groups ( Table 1) .
The clinical presentations of the patients in the LPSP and PA groups were similar, with the most common sign being jaundice. There was a trend toward more pronounced weight loss in the LPSP patients, but this did not reach statistical significance. The LPSP patients were less likely (33% vs. 80%) to have a discrete mass on computed tomog- raphy (CT) and more likely (33% vs. 0%) to have CT findings suggesting a diffusely enlarged pancreas (both P Ͻ .05; Table 2 ). The characteristic CT appearance of LPSP is presented in Figure 2 . An equal percentage of LPSP and PA patients underwent preoperative biliary decompression (81% [30/37] vs. 82% [37/45]). All patients undergoing pancreaticoduodenectomy for LPSP were initially thought to have malignant disease: the preoperative clinical diagnosis was pancreatic cancer in 53% (18/34), periampullary neoplasm in 38% (13/34), and cholangiocarcinoma in 9% (3/34).
Seventy percent (26/37) of the LPSP patients underwent pylorus-preserving pancreaticoduodenectomy (PPPD), whereas 67% (30/45) of the PA patients underwent PPPD. All remaining patients underwent classic pancreaticoduodenectomy. The operative notes of the patients undergoing surgery for LPSP were less likely (82% vs. 98%) to describe a discrete pancreatic mass, more likely (88% vs. 33%) to describe a diffusely firm or hard gland, and more likely (71% vs. 44%) to describe difficulty in dissecting the pancreas from the superior mesenteric vein/portal vein complex when compared to the operative notes of the PA patients (all P Ͻ .05). There was significantly greater operative blood loss in the LPSP group (1,290 mL [range 250 -5,200] vs. 832 mL [range 250 -3,000]; P Ͻ .05) and a trend toward a greater operative time in the LPSP group (401 minutes [range 289 -643] vs. 362 minutes [range 253-555]; P ϭ .056). The median length of stay was 9 days in the LPSP group and 8 days in the PA group. There were no differences in the rate of delayed gastric emptying, wound infection, pancreatic fistula, or overall complications ( Table 3) .
The median follow-up for all patients was 33 months. Using the Social Security Death Index (www.ssdi.genealogy.rootsweb.com), two people (ages 91 and 79) were found to have died at 4 and 6 years following surgery. Thirtyseven percent of the patients with LPSP developed diabetes after their surgery; 35% described occasional diarrhea. Following a typical presentation with significant weight loss, 48% of the LPSP patients gained weight following surgery. No patients noted nausea or recurrent jaundice, while one patient with LPSP suffered recurrent episodes of acute pancreatitis manifested by abdominal pain and elevated serum amylase and lipase levels. Four patients with LPSP underwent seven subsequent operations (laparotomy for bowel obstruction, n ϭ 2; ventral hernia repair, n ϭ 5).
Twenty-four of the 37 LPSP patients were currently available for telephone interview. When asked to compare their current quality of life relative to quality of life before surgery, 68% of the patients with LPSP reported improvement, 18% reported no change, and 14% reported a decreased quality of life.
DISCUSSION
LPSP is a variant of chronic pancreatitis occurring in the absence of gallstones, pancreas divisum, excess alcohol ingestion, or other factors commonly associated with pan- Lymphoplasmacytic Pancreatitis creatitis. It is characterized histologically by a diffuse lymphoplasmacytic infiltrate centered around pancreatic ducts and ductules, obliterative phlebitis, acinar atrophy, and interstitial fibrosis. 1,3-7 LPSP was first described in 1961 by Sarles et al., who suggested an etiology involving "a phenomenon of self-immunization." 1 In their report they also noted that two of the patients had hypergammaglobulinemia. Since that time, further characterization of LPSP, or autoimmune pancreatitis, has been primarily provided by Japanese centers. In 1995, Yoshida et al. proposed the idea of chronic pancreatitis caused by an autoimmune abnormality. 2 That paper described a patient with pancreatitis who had hyperglobulinemia, was autoantibody-positive, and responded to steroid therapy. The report included the description of 10 additional patients in the Japanese and English literature with pancreatitis suspected of being caused by an autoimmune mechanism. Since that report, other authors have published small series or case reports of autoimmune pancreatitis. 7, [12] [13] [14] [15] 17 Others have described the association of LPSP with Sjogren syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, Crohn disease, and ulcerative colitis. 6,8 -11 Finally, the cellular mechanisms contributing to LPSP are beginning to be elucidated. Okazaki et al. have proposed that an autoimmune mechanism against carbonic anhydrase II or lactoferrin and a Th1-type immune response may be involved in LPSP. 16 Hahm et al. have shown that loss of transforming growth factor-␤ signaling contributes to LPSP. 22 Perhaps most interesting has been the clinical improvement observed in patients with LPSP following steroid treatment. 2, 12, 13, 15, [17] [18] [19] Given that many of the patients with LPSP in the literature have undergone laparotomy based on an inaccurate suspicion of malignancy, it is intriguing to consider that successful steroid treatment may avoid unnecessary surgery. This approach obviously requires a preoperative diagnosis, which may be possible given the recently described association of elevated IgG4 levels and LPSP. 18, 23 Obviously, any strategy of nonoperative management must involve appropriate caution to avoid delayed diagnosis and treatment of a periampullary malignancy. In this regard, strict criteria for the nonoperative diagnosis of LPSP are currently lacking, and development of such criteria will be required for critical evaluation of outcomes following nonoperative management.
To further evaluate our institution's experience with LPSP, we searched our database of pancreaticoduodenectomies from January 1992 to May 2002 and found that 176 of 1,648 pancreaticoduodenectomies had been performed for chronic pancreatitis. These 176 cases were then reviewed, and 37 were classified as LPSP based on histologic criteria. We elected to compare the LPSP patients to a consecutive group of patients who underwent pancreaticoduodenectomy for PA to identify differences in presentation and outcome.
The mean age of our LPSP patients was 62 years and did not differ from that of the patients with PA. This finding coincides with a review of 37 cases of LPSP in Japanese patients, in which the mean age was 60 years. 15 Twentyfour percent of the LPSP patients in our study were female, which differed significantly from 64% in the PA group; however, this observation is consistent with the 1:2 femaleto-male ratio reported in Japanese LPSP patients. 15 There were no differences in the LPSP and PA groups with regard to a history of diabetes, pancreatitis, or alcohol use. However, 24% of the LPSP patients and none of the PA patients had an associated atopic or autoimmune disease (asthma, n ϭ 6; Sjogren syndrome, n ϭ 1; ulcerative colitis, n ϭ 2). This value is lower than the 60% rate of association with autoimmune disease in Japanese LPSP patients. 15 The clinical presentation of our LPSP and PA patients was very similar. There were no statistically significant differences in the rates of abdominal pain, weight loss, or jaundice. Our 84% rate of jaundice equaled the 81% observed in Japanese LPSP patients. 15 We also could find no difference in preoperative CEA or CA19-9 levels between the LPSP and PA groups. The only retrospectively identified preoperative variable that might have distinguished LPSP from PA was the appearance of the pancreas on CT. Only 33% of the LPSP patients had a discrete mass described on CT, whereas 80% of the PA patients had a discrete lesion. Further, 33% of the LPSP patients and none of the PA patients had a gland that was described as diffusely enlarged. Gland enlargement was noted in 68% of the Japanese LPSP patients. 15 These data regarding CT characteristics must be interpreted with some caution, as only 12 of 37 LPSP patients and 25 of 45 PA patients had dynamic, helical CT scans performed at our institution. Finally, although 81% of the LPSP patients underwent preoperative biliary drainage, only 30% had their procedure done at our institution, and none of these procedures included a pancreatogram that was available for review. The absence of a pancreatogram may have further diminished the likelihood of accurate preoperative diagnosis, as diffuse, irregular narrowing of the main pancreatic duct on pancreatogram was found in 75% of the Japanese LPSP patients. 15 Given the similarity in the presentations of the LPSP and PA groups, it is not surprising that the preoperative diagnosis in the LPSP group was pancreatic cancer in 53%, periampullary neoplasm in 38%, and cholangiocarcinoma in 9%, with no patient predicted to have LPSP based on preoperative findings. Our comparison of the operative data for the LPSP and PA patients suggests that a distinction may be made between the two disease processes based on operative findings, and that a pancreaticoduodenectomy performed in the setting of LPSP is more difficult than one performed for pancreatic ductal adenocarcinoma. Though the majority of both the LPSP and PA patients had a discrete mass noted at exploration, there was a difference, with 98% of the PA patients and only 82% of the LPSP patients thought to have a discrete mass in the pancreatic head. More importantly, 88% of the LPSP patients and only 33% of the PA patients had glands that were described as either diffusely firm or diffusely hard. Finally, a greater percentage, 71% versus 44%, of the LPSP patients were noted to have a difficult dissection of their pancreatic head from the portal vein/ superior mesenteric vein complex. When these more subjective operative data are combined with a significantly greater blood loss in the LPSP group and a trend toward a greater operative time, one could conclude that a pancreaticoduodenectomy is typically more difficult when performed for LPSP than when performed for PA. As for the initial postoperative course of the patients, there were no differences in length of stay, wound infection, pancreatic fistula, delayed gastric emptying, or overall complication rate. In addition, postoperative length of stay was similar for the two groups, suggesting that the increased technical difficulty associated with surgery for LPSP did not translate into a more complicated postoperative course.
Long-term follow-up of the LPSP patients suggests that most had a successful outcome following pancreaticoduodenectomy. Two people died, at 4 and 6 years postoperatively. Although the cause of death was not known, these patients were 91 and 79 years old, respectively. Thirty-five percent of the patients who did not have diabetes at the time of their surgery subsequently developed glucose intolerance. Whether the new-onset diabetes was due to surgical reduction of pancreatic mass or due to progression of fibrosis is not known. Diarrhea has been an occasional problem for 35% of the patients, but abdominal pain and nausea have not been problematic. One patient developed recurrent episodes of acute pancreatitis, which was presumed to represent a manifestation of ongoing LPSP. Finally, at a median follow-up of 33 months in our series, most of the LPSP patients (68%) reported their quality of life was better than before surgery. About half of the remaining patients said their quality of life was the same, and the other half said it was worse. These subjective data corroborate the symptomatic improvement noted following surgery.
Given today's diagnostic armamentarium of three-dimensional multidetector CT, ERCP, MRI/MRCP, and endoscopic ultrasound, it is increasingly less common that a preoperative diagnosis of periampullary cancer yields a pancreaticoduodenectomy specimen without cancer. The literature suggests that benign pathology will be encountered in 3% to 9% of pancreaticoduodenectomies done for presumed periampullary cancer. 20,24 -27 In virtually all of these instances, chronic pancreatitis is responsible for signs and symptoms frequently associated with pancreatic malignancy.
LPSP mimics PA in clinical presentation, though CT findings of a diffusely enlarged gland without a discrete mass may suggest a diagnosis of LPSP. A preoperative diagnosis of LPSP might be further corroborated by the finding of diffuse, irregular narrowing of the main pancreatic duct on pancreatography. In patients presenting with these findings on pancreatic imaging, elevation of serum IgG4 levels suggests the diagnosis of LPSP. In patients with both radiographic and serologic suspicion of LPSP and with a negative FNA or biopsy, a carefully monitored course of steroid therapy may provide symptomatic relief. Nevertheless, the majority of patients with LPSP will likely continue to be managed by pancreaticoduodenectomy, based on an inability to exclude the possibility of pancreatic neoplasia. The current data suggest that this approach is associated with durable relief of symptoms and improved quality of life.
Since submission of this manuscript, a similar surgical experience with LPSP has been published by Weber, et al. (J Gastrointest Surg. 2003; 7:129 -37) . "Well, this man is elderly, this may not be pancreas cancer, it might not be a bad idea to wait," and do you intend to do that? We have actually done this in two patients. It is an uncomfortable business. Would you comment on that?
DR. STEVEN D. LEACH (Baltimore, MD): I want to thank all of the discussants for their insightful comments, and also thank the Association for the privilege of presenting our experience with this uncommon mimic of pancreatic cancer.
Dr. Nealon asked several interesting questions. First, could this entity possibly be more common than we have recognized to date? In this regard, I can only relate that we reviewed all patients undergoing pancreatic head resection for chronic pancreatitis in our institution, and our 20% reported incidence of LPSP in this group was obtained by the application of very strict histologic criteria. A diagnosis of LPSP required the presence of chronic pancreatitis with a lymphoplasmacytic infiltrate, associated periductal inflammation, and obstructive venulitis. Applying those rigid criteria, our incidence is 20%. This figure appears to have some validity, inasmuch as the Memorial group has reported an almost identical figure.
Are there other subtypes of this already rare entity that may not fulfill all three of those criteria? Perhaps. Our study also identified only those patients with LPSP who underwent pancreaticoduodenectomy, so I think the jury is out on what the true incidence might be.
Dr. Nealon also asked whether there might be any other imaging studies that might distinguish this entity from more typical forms of chronic pancreatitis. Rather than relying on a single imaging modality, the diagnosis of LPSP is probably best made by a panel of diagnostic studies. We have observed a fairly striking CT appearance in certain cases, involving diffuse enlargement of the gland and loss of parenchymal markings. Clearly, the pancreaticogram appearance of this disease is fairly distinctive in terms of diffuse irregular narrowing of the duct, although this can certainly also be observed in cases of small duct chronic pancreatitis. It has been described that LPSP typically appears as a hypoechoic entity on sonographic imaging, and it is possible that EUS will help to distinguish this entity from other forms of chronic pancreatitis in the future. Certainly with respect to the distinction from pancreatic cancer, one might suggest that FDG-PET might be useful in distinguishing these entities.
In terms of the duration of symptoms between this group of patients and our pancreatic cancer patients, it is really very similar. There is the relatively abrupt onset of weight loss, abdominal pain, and jaundice, typically with the history of 1 to 2 months before referral to our institution, similar to the majority of patients with pancreatic cancer. So this does not suggest an ongoing, undetected, smoldering process.
Dr. Nealon also asked whether serologic testing might identify an increased incidence of associated autoimmune disease in these patients. Inasmuch as the bulk of our patient population was identified only following pathologic review of patients undergoing pancreatic head resection for what was initially reported as chronic pancreatitis, we did not consistently perform serologic evaluation on these patients. The realization that patients with LPSP have an abnormal serum IgG profile has only recently been reported in the literature, and the question of other associated serologic abnormalities remains to be determined.
In terms of weight gain following resection, this was very informative, actually, in support of our impression that patients did have an improved quality of life following resection. We saw a number of patients who had very dramatic weight loss before surgery. Against this background, half of our patients did gain weight postoperatively, even in the setting of having undergone pancreaticoduodenectomy.
Dr. Gadacz asked whether endoscopic ultrasound and cytology might allow this entity to be accurately diagnosed before surgery. The current experience with cytologic evaluation of this entity suggests that FNA is not a means of accurate diagnostic confirmation. In a number of reports, the cytologic appearance of LPSP has been rather nondescript, so cytologic features do not appear to be a likely means of increasing our preoperative diagnostic accuracy.
In response to Dr. Blumgart's question, have we avoided surgery in patients with obstructive jaundice and the presumptive diagnosis of LPSP? We have not yet identified patients with elevated serum IgG4 levels in whom we have avoided operation. We have, however, begun to send IgG4 levels on patients with suspected LPSP. In a single patient with LPSP and a normal preoperative IgG4 level, we have made the intraoperative assessment of chronic pancreatitis and avoided pancreaticoduodenectomy. But to date we have not encountered patients in whom we have been able to avoid operation altogether. Now that we have recognized this entity, there is certainly hope that we might be able to pursue nonoperative management in the future. Lymphoplasmacytic Pancreatitis
